NCT05388123View on ClinicalTrials.gov

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Hairy Cell Leukemia
Interventions
DRUG

Low dose vemurafenib plus rituximab

Vemurafenib 240 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib

Trial Locations (1)

92037

Scripps Cancer Center, La Jolla

All Listed Sponsors
lead

Scripps Health

OTHER